News
-
-
-
COMMUNIQUÉ DE PRESSE
enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment
enVVeno Medical CEO, Robert Berman, to participate in a live webcast on December 3rd, providing corporate overview and answering questions. Focus on bioprosthetic solutions for deep venous disease -
-
-
COMMUNIQUÉ DE PRESSE
enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve
enVVeno Medical Corporation receives unfavorable FDA decision on VenoValve, plans to focus on next-generation venous valve enVVe. Company has sufficient cash for operations into 2027. Severe CVI impacts millions in the U.S -
-
-
COMMUNIQUÉ DE PRESSE
enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update
enVVeno Medical Corporation reports financial results for Q3 2025, with $31.0 million in cash and ongoing FDA engagement for VenoValve. CEO comments on capitalization and clinical progress -